Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7091MR)

This product GTTS-WQ7091MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7091MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2643MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ7312MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ11879MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ11155MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ15863MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ8689MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ6595MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ14686MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW